Skip to main content
. 2008 Mar;2(1):1–14. doi: 10.2147/opth.s1959

Figure 4.

Figure 4

In patients with classic subfoveal CNV due to AMD, ranibizumab prevented visual loss in a significantly higher number of patients than PDT (12-month results modified according to Brown et al 2006; 24-month results according to Schmidt-Erfurth et al 2007).